Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study

Apisarnthanarax, Narin; Talpur, Rakhshandra; Ward, Staci; Ni, Xiao; Kim, Hyung Woo; Duvic, Madeleine

doi:10.1016/j.jaad.2003.09.005

Cited by 57 publications

(24 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is further supported by a recent report on longterm remissions in patients with early-stage disease treated with psoralens and ultraviolet light A (PUVA) [28 •• ]. Besides the standard skin-directed therapies such as phototherapy with PUVA or narrowband ultraviolet B, topical steroids, topical chemotherapy with nitrogen mustard or carmustine, bexarotene gel, and total skin electronbeam therapy, new treatment approaches with alternative retinoids such as tazarotene and topical immunomodulators such as imiquimod have shown efficacy in a small number of patients with early CTCL [29,30]. Moreover, treatment with 308-nm excimer laser might be an option in selected instances resistant to phototherapy [31,32].…”

Section: Treatment Of Early-stage Diseasementioning

confidence: 99%

The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy

Querfeld¹,

Rosen

Guitart³

et al. 2005

Current Opinion in Hematology

View full text Add to dashboard Cite

show abstract

Section: Treatment Of Early-stage Diseasementioning

confidence: 99%

The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy

Querfeld¹,

Rosen

Guitart³

et al. 2005

Current Opinion in Hematology

View full text Add to dashboard Cite

show abstract

“…Topical bexarotene in gel form is a synthetic retinoid-X-receptor-selective retinoid, which has The rate of irritation was similar or slightly higher than that reported with topical bexarotene gel for MF lesions, but the pilot study with tazarotene included few patients, was non-randomized, had no vehicle control and was susceptible to bias in lesion assessments [14] . Nonetheless, these data suggest that tazarotene 0.1% gel combined with topical corticosteroids may be an effective adjuvant therapy for refractory MF lesions.…”

Section: Tazarotenementioning

confidence: 87%

New and Experimental Skin-Directed Therapies for Cutaneous Lymphomas

Farkas

Kemény

French

et al. 2009

Skin Pharmacol Physiol

View full text Add to dashboard Cite

Primary cutaneous lymphomas (CLs) originate in the skin and should be differentiated from secondary skin infiltrates, which are manifestations of lymphomas of nodal or extranodal origin. These rare diseases include various lymphoproliferative disorders: cutaneous T-cell lymphomas, cutaneous Bcell lymphomas and some rare subtypes. As definitive cure is often not possible, it is important to control the disease and alleviate symptoms. Patients with early-stage disease limited to the skin usually require skin-directed therapies using topical agents including corticosteroids, chemotherapeutic drugs, bexarotene gel, electron beam therapy and phototherapy. Each of these are effective; however, all have some disadvantages and are associated with significant adverse events. In the field of skin-directed therapies there are interesting developments using antineoplastic compounds, the retinoid tazarotene, imiquimod, gene therapy products (adenovirus vector expressing gamma-interferon), the monoclonal anti-CD20 antibody rituximab, photodynamic therapy and 308-nm excimer laser to mention a few. This review highlights some of the promising new and experimental local therapies for primary CLs and focuses on their efficacy and side effects.

show abstract

“…Its use as a topical agent in MF has been assessed in a single pilot study of 20 patients with treatment-refractory MF. 81 Patients applied 0.1% tazarotene gel once daily to lesional skin, with 58% of patients experiencing greater than a 50% improvement in index lesions but no patients showing a CR. These patients were allowed to use topical steroids concomitantly with their treatment to reduce cutaneous irritation.…”

Section: Bexarotenementioning

confidence: 99%

Skin-Directed Therapies in Cutaneous T-Cell Lymphoma

Nguyen

Bohjanen

2015

Dermatologic Clinics

View full text Add to dashboard Cite

Early stage mycosis fungoides represents the most common clinical presentation of cutaneous lymphoma, with skin-directed therapies long established in its treatment. These therapies continue to change as new treatment regimens emerge. Other skin-directed treatments include light and radiation therapy. Therapies with higher levels of evidence and less systemic toxicity are usually preferred as first-line treatment. However, even these established therapies, like topical corticosteroids and carmustine, lack randomized clinical trials to establish their efficacy. Research is also needed to further define the role of combination topical therapies and how skin-directed therapies can be used as adjuvants to systemic medications.

show abstract

Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study

Cited by 57 publications

References 21 publications

The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy

The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy

New and Experimental Skin-Directed Therapies for Cutaneous Lymphomas

Skin-Directed Therapies in Cutaneous T-Cell Lymphoma

Contact Info

Product

Resources

About